Brokers Set Expectations for MAZE Q2 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – HC Wainwright issued their Q2 2027 earnings per share estimates for shares of Maze Therapeutics in a note issued to investors on Monday, October 5th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($0.65) per share for the quarter. HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q3 2027 earnings at ($0.65) EPS.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76).

Other research analysts also recently issued research reports about the stock. Wedbush reissued an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Citigroup assumed coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Price Performance

MAZE opened at $26.43 on Tuesday. The firm has a market cap of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. The business’s fifty day simple moving average is $26.90 and its 200 day simple moving average is $27.74. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Insiders Place Their Bets

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of Maze Therapeutics stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the sale, the insider owned 7,007 shares in the company, valued at $182,252.07. The trade was a 22.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $27.06, for a total transaction of $202,950.00. Following the transaction, the insider directly owned 32,316 shares of the company’s stock, valued at approximately $874,470.96. This represents a 18.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 192,991 shares of company stock valued at $5,152,084 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC grew its stake in shares of Maze Therapeutics by 42.8% during the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock valued at $580,000 after buying an additional 5,822 shares during the period. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the period. AXQ Capital LP boosted its holdings in Maze Therapeutics by 114.1% in the second quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after acquiring an additional 8,098 shares during the last quarter. Braidwell LP acquired a new position in Maze Therapeutics in the second quarter valued at $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Maze Therapeutics by 4,054.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after acquiring an additional 17,312 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.